Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants
The Journal of Infectious Diseases · 15.05.2024 · 229 (5) · 1290-1294
DOI: 10.1093/infdis/jiad562 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 07.12.2023. Verfasst von Robert A Smith und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle. Hauptthemen laut MEDLINE: HIV-2, Drug Resistance, Viral. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, (NIAID).
Abstract (Originalsprache)
The activity of lenacapavir against human immunodeficiency virus type 1 (HIV-1) has been extensively evaluated in vitro, but comparable data for human immunodeficiency virus type 2 (HIV-2) are scarce. We determined the anti–HIV-2 activity of lenacapavir using single-cycle infections of MAGIC-5A cells and multicycle infections of a T-cell line. Lenacapavir exhibited low-nanomolar activity against HIV-2, but was 11- to 14-fold less potent against HIV-2 in comparison to HIV-1. Mutations in HIV-2 that confer resistance to other antiretrovirals did not confer cross-resistance to lenacapavir. Although lenacapavir-containing regimens might be considered for appropriate patients with HIV-2, more frequent viral load and/or CD4 testing may be needed to assess clinical response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle.
- Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle.
- Service des Maladies Infectieuses et Tropicales, Centre Hospitalier National Universitaire de Fann, Dakar, Senegal.
- Clinical Virology, Gilead Sciences Inc, Foster City, California.
- Department of Global Health, University of Washington, Seattle.
ORCID-Profile: Robert A Smith, Geoffrey S Gottlieb
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- (NIAID)
- NIH HHS
- University of Washington Center for AIDS Research
- Stanford HIV Drug Resistance Database Program
- National Institutes of Health
Zitieren
APA
Smith, R. A., Raugi, D. N., Nixon, R. S., Seydi, M., Margot, N. A., Callebaut, C., Gottlieb, G. S., & University of Washington–Senegal HIV-2 Study Group (2024). Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants. The Journal of Infectious Diseases, 229(5), 1290-1294. https://doi.org/10.1093/infdis/jiad562
Vancouver
Smith RA, Raugi DN, Nixon RS, Seydi M, Margot NA, Callebaut C, et al. Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants. The Journal of Infectious Diseases. 2024;229(5):1290-1294. doi:10.1093/infdis/jiad562
BibTeX
@article{Smith2024,
author = {Smith, Robert A and Raugi, Dana N and Nixon, Robert S and Seydi, Moussa and Margot, Nicolas A and Callebaut, Christian and Gottlieb, Geoffrey S and University of Washington–Senegal HIV-2 Study Group, University of Washington–Senegal HIV-2 Study Group},
title = {Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants},
journal = {The Journal of Infectious Diseases},
year = {2024},
volume = {229},
number = {5},
pages = {1290--1294},
doi = {10.1093/infdis/jiad562}
}
EUVIMED